German firm Biotronik has reported positive results from the BIOFLEX-I clinical trial of the Pulsar-18 stent to treat patients suffering from peripheral artery disease (PAD).
Pulsar-18 is a superficial femoral artery (SFA) self-expanding stent that features a 4-French (4F) delivery system to allow simple, safe and efficient procedures compared to delivery systems with a larger diameter.
The device also mitigates procedural duration as the 4F system enables easy crossing of lesions, decreasing access site complication rates as well as compression time by eliminating the requirement for a closure device.
